Emerging anti-spike monoclonal antibodies against SARS-CoV-2
EE Ordaya, RR Razonable - Expert Opinion on Biological Therapy, 2024 - Taylor & Francis
Introduction Anti-spike monoclonal antibodies (mAbs) were previously authorized for the
prevention and treatment of COVID-19 in immunocompromised patients. However, they are …
prevention and treatment of COVID-19 in immunocompromised patients. However, they are …
Prevention of COVID-19 following a single intramuscular administration of adintrevimab: results from a Phase 2/3 randomized, double-blind, placebo-controlled trial …
MG Ison, DF Weinstein, M Dobryanska… - Open Forum …, 2023 - academic.oup.com
Background The prevention of coronavirus disease 2019 (COVID-19) in vulnerable
populations is a global health priority. EVADE was a phase 2/3 multicenter, double-blind …
populations is a global health priority. EVADE was a phase 2/3 multicenter, double-blind …
Diagnóstico serológico en pacientes tras infección por SARS-CoV-2. Estudio de neutralización en profesionales sanitarios tras vacunación
E Serrano-Conde Sánchez - 2024 - digibug.ugr.es
Desde diciembre de 2019 el mundo ha vivido una situación sin precedentes en la historia
reciente. Desde China, se propagó un virus hasta el momento desconocido. Gracias a la …
reciente. Desde China, se propagó un virus hasta el momento desconocido. Gracias a la …
Monoclonal antibodies in therapy of COVID-19
A Gicheva Pepovska - 2023 - repozitorij.pharma.unizg.hr
OBJECTIVES: The aim of this research is to present an overview of current knowledge about
the possibilities and challenges of mAbs therapy in treating COVID-19 in patients with high …
the possibilities and challenges of mAbs therapy in treating COVID-19 in patients with high …